Differential plasma exosomal long non-coding RNAs expression profiles and their emerging role in E-cigarette users, cigarette, waterpipe, and dual smokers

Gagandeep Kaur¹, Kameshwar Singh¹, Krishna P. Maremanda¹, Dongmei Li², Hitendra S. Chand³, Irfan Rahman¹*¹

¹ Department of Environmental Medicine, University of Rochester Medical Center, Rochester, NY, United States of America, ² Department of Clinical & Translational Research, University of Rochester Medical Center, Rochester, NY, United States of America, ³ Department of Immunology and Nanomedicine, Florida International University, Miami, FL, United States of America

* irfan_rahman@urmc.rochester.edu

Abstract

Long non-coding RNAs (lncRNAs) are the varied set of transcripts that play a critical role in biological processes like gene regulation, transcription, post-transcriptional modification, and chromatin remodeling. Recent studies have reported the presence of lncRNAs in the exosomes that are involved in regulating cell-to-cell communication in lung pathologies including lung cancer, chronic obstructive pulmonary disease (COPD), asthma, and idiopathic pulmonary fibrosis (IPF). In this study, we compared the lncRNA profiles in the plasma-derived exosomes amongst non-smokers (NS), cigarette smokers (CS), E-cig users (E-cig), waterpipe smokers (WP) and dual smokers (CSWP) using GeneChip™ WT Pico kit for transcriptional profiling. We found alterations in a distinct set of lncRNAs among subjects exposed to E-cig vapor, cigarette smoke, waterpipe smoke and dual smoke with some overlaps. Gene enrichment analyses of the differentially expressed lncRNAs demonstrated enrichment in the lncRNAs involved in crucial biological processes including steroid metabolism, cell differentiation and proliferation. Thus, the characterized lncRNA profiles of the plasma-derived exosomes from smokers, vapers, waterpipe users, and dual smokers will help identify the biomarkers relevant to chronic lung diseases such as COPD, asthma or IPF.

Introduction

A large proportion of human genome encodes for the long non-coding RNAs (lncRNAs), a diverse set of transcripts that do not encode for any functional protein. LncRNA transcripts are larger than 200 nucleotides in length and include, intronic lncRNA, long intergenic non-coding RNAs (lincRNAs), pseudogenic transcripts, circular RNAs (circRNA), long enhancer noncoding RNAs (eRNAs), natural antisense transcripts (NATs), and transcribed ultra-conserved regions (TUCRs) [1, 2]. Studies have shown that lncRNAs play crucial role in various
biological processes including gene regulation, gene transcription, post-transcriptional modification, and chromatin remodeling in health and disease [3, 4]. Current IncRNA database report that there are around 127,802 putative IncRNAs encoded by human genome and are highly abundant than the number of protein-coding genes [5], however, not much is known about their role in regulating the physiological responses to environmental exposures such as tobacco smoke.

In the last few years, IncRNAs are identified in the exosomes (the extracellular vesicles known to be essential for cell-to-cell communication) [6, 7]. Exosomes are the smallest subtype of extracellular vesicles (30–150 nm in size) surrounded by phospholipid bilayer [7, 8]. They are present in various biofluids including blood plasma, breast milk, urine, saliva, and bronchoalveolar lavage [9, 10]. Importantly, exosomal IncRNAs are being extensively investigated as potential diagnostic biomarkers for various disease conditions, importantly cancers [7, 10]. Yet, despite the growing interest in this area, little is known about their physiological function and role in other inflammatory disease conditions.

In this respect, evidences of involvement of exosomal IncRNA in lung pathologies including lung cancer, tuberculosis (TB), chronic obstructive pulmonary disease (COPD), asthma, and interstitial lung disease (ILD) are increasing [1, 11–15]. It has been demonstrated that the exosomal microRNAs (miRNA) and IncRNA profiles among patients with pulmonary pathologies are quite distinct than healthy individuals [12, 14, 16, 17]. Microarray analyses of IncRNA population in the lung tissues from non-smokers without COPD and smokers with or without COPD detected alteration in distinct classes of IncRNA, cigarette smoke exposure is associated with changes in IncRNAs which play an important role in the activation of metabolic pathways, whereas COPD onset and progression was attributed to activation of IncRNAs involved in intermediary metabolism and immune system processes [18]. It is likely that tobacco smoke exposure can alter the IncRNA profile of the lung tissue that can be involved in the pathogenesis of lung diseases.

Smoking habits amongst adults and adolescents are not only confined to combustible tobacco cigarettes but now has expanded to other tobacco products. In the last few decades, the popularity of E-cigarette and related products is on a rise amongst young adults in the US [19, 20]. At the same time, the prevalence of ‘hookah’ or waterpipe is also increasing [21, 22]. Considering this and based on our recent observations of differential regulation of miRNA [23], we compared the expression profiles of plasma-derived exosomal IncRNAs from non-smokers (NS), cigarette smokers (CS), E-cig users (E-cig), waterpipe (WP) users and dual (cigarette and waterpipe) smokers (CSWP). The objective of this study was to characterize the IncRNA content of the plasma-derived exosomes from a representative population of these tobacco product users to help identify novel biomarkers, which may be relevant to the associated pulmonary pathologies, such as COPD, asthma, and IPF.

Materials and methods

Ethics approval and consent to participate

The Institutional Review Board (IRB) /Research Subject Review Board (RSRB) committee at the University of Rochester Medical Center, Rochester, NY with an approval number CR00002635, approved all the protocols and procedures. All the study participants recruited for the study signed an informed written consent form before recruitment and sample collection (August 2017 until February 2020).

Human study protocol: Yes; Animal study protocol: None; Institutional biosafety approvals: Yes. The University of Rochester Institutional Biosafety Committee approved the study (study approval number: Rahman/102054/09-167/07-186; identification code: 07–186; date of approval: 5 January 2019).
Study design and subject recruitment

We employed the blood samples collected during the cross-sectional pilot study from 2017–2019 for exosome isolation and lncRNA expression analyses. A detailed description of the study subject recruitment and their inclusion/eligibility and exclusion criteria were reported previously [24, 25]. In brief, n = 6–8 subjects (equal number of males and females based on local demography) were selected in each group. Our subject groups included; (a) non-smokers/non-users, (b) E-cigarette users, (c) cigarette smokers, (d) waterpipe smokers, and (e) dual smokers comprising both waterpipe and cigarette smokers. The study participants were recruited at the General Clinical Research Center at the University of Rochester Medical Center, Rochester, NY with the help of local newspaper and magazine advertisements. Each subject filled a questionnaire containing information about demographics, clinical symptoms, E-cig use, and vaping history [25, 26]. We collected 20–25 ml blood by venipuncture from smokers (CS), vapers (E-cig), waterpipe (WP) users, and subjects indulged in both cigarette smoking and waterpipe use (CSWP) as previously shown [23, 26]. Subjects included for the study were between 18–65 yrs. in age and reported at least 6 months of E-cig or tobacco use (at least once daily). Subjects with pre-existing conditions (bronchiectasis, lung cancer, COPD, asthma, cystic fibrosis, congestive heart failure, or other chronic illness) or using any medication (systemic corticosteroid or anti-inflammatory therapy) were not included in the study. Likewise, pregnant or lactating females were not recruited in this study. The smoking status of the subjects was confirmed by performing plasma cotinine assay [24, 25].

Plasma exosome isolation

We employed commercially available kit from Norgen Biotek (Cat# 57400; Ontario, Canada) to isolate exosomes from human plasma. Plasma exosomes were isolated as per manufacturer’s protocols as described earlier [23, 27]. In brief, 1 ml plasma was centrifuged at 400 g (~2000 rpm) for 2 min. The supernatant was collected and mixed with 3 ml nuclease-free water,100 μl ExoC buffer and 200 μl of Slurry E and incubated for 5 minutes at room temperature. Thereafter, the tubes were centrifuged at 2000 rpm for 2 minutes and the supernatant was discarded. Next, 200 μl of ExoR buffer was added to the slurry pellet and mixed. This solution was incubated at room temperature for 5 minutes after which the tubes were again centrifuged at 500 rpm for 2 minutes. Finally, the supernatant was transferred to a mini filter spin column to elute the exosomal fraction following centrifugation at 6000 rpm for 1 minute. The eluted exosomes were stored at -80˚C until further use.

Exosome characterization

Transmission electron microscopy (TEM) was used to visualize the isolated exosomes and nanoparticle tracking analysis was performed to analyze the particle size and concentration as described [23].

Exosomal RNA extraction

Total RNA from exosomes was isolated using Exosomal RNA isolation kit (Norgen Bioteck Corporation, Cat# 58000) as per the manufacturer’s protocol. The detailed procedure has been published earlier [23]. The RNA quality and quantity were checked using NanoDrop ND-1000 spectrophotometer (Thermo Fisher Scientific, Wilmington, DE).

Transcriptome library preparation

We employed the GeneChip™ WT Pico kit (Cat# 902622 and 902623, Applied Biosystems, Foster city, CA) for transcriptome profiling of the RNA isolated from various experimental
groups. This highly sensitive and flexible assay is used to assess the RNA expression from as little as 100 picogram of total RNA. The assay ensures strand specificity and can perform multiple layers of analysis in combination with transcriptome arrays to accurately measure gene- or transcript-level expression of coding as well as long non-coding RNA [28].

The Microarray & NextGen Sequencing Core at the Center for Functional Genomics at SUNY, Albany performed the library preparation and microarray hybridization. In brief, 100 pg of high-quality total RNA was reverse transcribed and amplified per manufacturer’s protocol. RNA amplification was achieved using low-cycle PCR followed by linear amplification with the help of T7 in vitro transcription (IVT) technology. The obtained complimentary RNA was then converted to biotinylated sense-strand cDNA targets for hybridization and unbiased coverage of the transcriptome.

Microarray and computational analysis
The single-stranded cDNA obtained from the previous step was mixed with the hybridization mixture and loaded onto the GeneChip Cartridge array provided with the kit and incubated for 16 hrs. at 45˚C and 60 rpm rotation in GeneChip™ Hybridization Oven. Thereafter, the array was washed, stained and scanned as per the manufacturer’s protocol. The data files obtained after the scan were analyzed using the Transcriptome Analysis Console (TAC 4.0.1) Software using the Data flow worksheet as provided by Affymetrix.

Statistical analysis
The long non-coding RNA (lncRNA) data from two batches were first normalized using the rma function in the R/Bioconductor. The annotation of the lncRNAs were obtained from the Clarion D human array from Affymetrix through the annotateEset function in R/Bioconductor. Boxplot was used to examine the distribution of the normalized lncRNA data from all samples. Multidimensional scaling (MDS) plot was used to determine the spatial distance between the lncRNA samples. Linear regression models with empirical Bayes approach was then used to fit the normalized lncRNA data with the batch effects and initial RNA quantity differences were adjusted. Linear contrasts within the linear regression model framework was further used to examine the differences in the comparisons between different groups of interest. Volcano plots were generated to highlight significant lncRNAs with significant fold changes (>2-fold changes) and raw P-values (less than 0.0001) using the EnhancedVolcano function in R/Bioconductor. Heatmaps were generated to show the lncRNA expressions in different groups using the heatmap function with ward. D2 method for clustering the significant lncRNAs in R/Bioconductor. To examine the overlaps in identified lncRNAs from related group comparisons, venn.diagram function in R/Bioconductor was used.

Results
lncRNAs expression profiling in plasma exosomes from non-smokers, cigarette smokers, E-cig users, waterpipe users and dual smokers
To understand the role of exosomal lncRNA in regulating downstream signaling amongst smokers, vapers, waterpipe and dual users, we first isolated the plasma exosomes from the blood of six study participants from each group. The isolated exosomes were characterized using immunoblotting and transmission electron microscopy (TEM) as published earlier [23]. Next, total RNA was isolated from the exosomal fractions and the expression profiling of the lncRNAs was performed.
The raw expression data from the lncRNAs expression profiling was normalized and plotted as a box plot as shown in Fig 1. We did not observe any changes in the data distribution across the groups after normalization and proceeded further with the analyses.

Multidimensional scaling (MDA) plot reveals the batch variations in the lncRNA expression data amongst the experimental groups

To visualize the similarities between each sample within the groups, we employed multidimensional scaling (MDS). MDS plot revealed the batch variations within the samples. The dual smokers (CSWP) group had minimum batch effects in the lncRNA expression as seen by their close clustering in the MDS plot based on batch 2 analyses. Rest of the four groups–NS, CS, E-cig and WP- showed variations (due to batch effect) as seen in Fig 2.

lncRNA from plasma exosomes of non-smokers, smokers, E-cig users, waterpipe users and dual smokers exhibit distinct expression profiles

We generated volcano plots showing pairwise comparisons of the differential expression profiles of the lncRNAs from various experimental groups (Fig 3). The volcano plots were plotted such that each of the significant differentially expressed lncRNAs in the treatment group versus the control are denoted as colored dots. Any fold change greater than ±1 on the logarithmic (base2) scale was considered significant in our study, and is denoted by green dots on the graph. A threshold of 4 for raw p-value on the logarithmic scale (base 10) was considered to be significant and has been plotted as blue and red dots in the graph. Importantly, the red dots denote the lncRNAs that are differentially expressed with a fold change greater than ±1 as compared to control and are statistically significant with raw p-value p<0.0001.
Hierarchical clustering shows significant variations in the lncRNA expression in plasma exosomes from non-smokers, smokers, E-cig users, waterpipe users and dual smokers.

Next, we plotted heatmaps showing the differential expression of lncRNAs comparing CS vs. NS, E-cig vs. NS, WP vs. NS, CSWP vs. NS, CS vs. E-cig, WP vs. E-cig, CSWP vs. E-cig, CS vs. WP, CSWP vs. CS and CSWP vs. WP, respectively in Fig 4A–4J. Each row in the heatmap represents individual lncRNAs and each column denotes individual sample. The color scale indicates the relative expression level of lncRNAs with green showing upregulation while red representing downregulation of gene expression. A detailed information about the identified differentially expressed genes along with fold change and p-value information is provided in Table 1. Briefly, the following observations were made from various pairwise comparisons:

Smokers vs non-smokers. We found 7 differentially expressed lncRNAs in the exosomes from blood plasma from CS as compared to NS. Two of those lncRNAs were upregulated while the rest where downregulated amongst smokers as compared to the NS controls (Fig 4A).

E-cig users vs non-smokers. In total, we observed 13 differentially expressed lncRNAs - eight upregulated and five downregulated- on comparing E-cig users with NS (Fig 4B). Interestingly, we found approximately 4-fold increase in the expression of BNIP3L, Bcl2 interacting protein 3-like protein (Fold change = 3.74; p = 2.8E-05) amongst the E-cig users as compared to the non-smoking controls. We further found an increase in the expression of lncRNA belonging to members of RNA binding [lozorby (Fold change = 1.64; p = 2.96E-05)] and endonuclease reverse transcriptase [zoyberby (Fold change = 1.81; p = 4.40E-05) and flarchoy (Fold change = 1.26; p = 7.32E-05)] protein family.

Waterpipe user vs non-smokers. We identified 18 differentially expressed lncRNAs in plasma exosomes on comparing WP group with NS (Fig 4C). Of these, 9 were upregulated while 9 others were found to be downregulated amongst the WP users as compared to the control (NS) group.

Fig 2. Multidimensional scaling plot (MDS) for the study group shows batch variations. MDS plot based on differential IncRNA expression in individual samples of non-smokers (NS), cigarette smokers (CS), E-cigarette users (E-cig), waterpipe smokers (WP) and dual smokers (CSWP).
On comparing lncRNA expression profiles of CSWP and NS groups, we found 9 differentially expressed lncRNAs in plasma exosomes, where four were downregulated and five upregulated in the plasma exosomes from dual smokers as compared to non-smokers. (Fig 3. Volcano plots showing number and distribution of lncRNAs. Volcano plot showing the relation between p-values (Y-axis) vs fold change (X-axis) in the differentially expressed lncRNAs amongst (A) Cigarette smokers vs. non-smokers, (B) E-cig users vs. Non-smokers, (C) waterpipe smokers vs. Non-smokers, (D) dual smokers vs. Non-smokers, (E) Cigarette smokers vs. E-cig users, (F) Cigarette smokers vs. waterpipe smokers, (G) Waterpipe smokers vs. E-cig users, (H) Dual smokers vs. E-cig users, (I) Dual smokers vs. cigarette smokers, and (J) Dual smokers vs. waterpipe smokers. Log₂ fold change (cut-off = ± 1, vertical lines) was plotted against the –log₁₀ p-value (cut-off = 4, horizontal line). Adjusted p-value, P < 0.0001. 

https://doi.org/10.1371/journal.pone.0243065.g003

**Dual smoker vs non-smokers.** On comparing lncRNA expression profiles of CSWP and NS groups, we found 9 differentially expressed lncRNAs in plasma exosomes, where four were downregulated and five upregulated in the plasma exosomes from dual smokers as compared to non-smokers.
Fig 4. Hierarchical cluster analyses of differentially expressed lncRNAs. Heat map showing differentially expressed lncRNAs that are significantly varied between (A) Non-smokers and cigarette smokers, (B) Non-smokers and E-cigarette users, (C) Non-smokers and waterpipe users, (D) Non-smoker and dual smokers, (E) Cigarette
to non-smoking controls (Fig 4D). Most of the differentially expressed lncRNAs identified on this comparison belonged to the family of putative proteins and thus have no known function. **Smokers vs. E-cig users.** A total of 22 lncRNAs were found to show significant differential expression in E-cig users in comparison to CS group (Fig 4E). Of these, 10 lncRNAs were downregulated whereas 12 showed increased expression in cigarette smokers when compared to E-cig users. Many of the identified differentially expressed RNAs belonged to intronic or non-protein coding regions as shown in Table 1.

**Waterpipe vs E-cig users.** We demonstrate 5 differentially expressed lncRNAs (4 upregulated while 1 downregulated) in the plasma exosomes from WP in comparison to E-cig users as depicted in Fig 4F and Table 1.

**Dual smoker vs E-cig users.** We identified 4 downregulated and 3 upregulated lncRNAs, on comparing the lncRNA expression in plasma exosomes from dual smokers with those of E-cig users (Fig 4G).

**Smokers vs waterpipe users.** Nine lncRNAs were found to be differentially expressed in plasma exosomes from cigarette smokers as compared to WP group. Of these, most (6) were downregulated (Fig 4H). Importantly, two exon coding genes- rarsybo (Fold change = -3.14; p = 3.00E-05) and warbo (Fold change = -2.67, p = 7.88E-05)—showed three-fold decrease amongst CS group as compared to WP users.

**Dual smoker vs smokers.** We observed 11 differentially expressed lncRNAs on comparing the lncRNA expression between dual and cigarette smokers. Nine out of eleven of the differentially expressed lncRNAs were downregulated in dual smokers as compared to CS control (Fig 4I).

**Dual smoker vs waterpipe users.** Lastly, on comparing the lncRNA expressions between CSWP and WP groups we identified 12 differentially expressed lncRNAs. Most (9 out of 12) of the identified lncRNAs were upregulated in the plasma exosomes from dual smokers as compared to waterpipe users (Fig 4J).

**lncRNA expression overlaps amongst various treatment groups**

To identify the lncRNAs that were commonly dysregulated on exposure to different types of exposures in our experiment, we performed a quick analysis of the differentially expressed lncRNAs and plotted a Venn diagrams to identify the common targets (Fig 5A–5E). The differentially expressed lncRNAs identified on comparing the expression profiles of the NS with E-cig users were distinct and did not show any overlap with other groups. One of the lncRNA gene ID (TC0900011940.hg.1) was found to be downregulated amongst both CS (Fold change = -0.72) and WP (Fold change = -0.71) groups when compared to NS. Similarly, another lncRNA (TC1100010467.hg.1) encoding for WT1 transcription factor was found to be downregulated amongst both waterpipe users (Fold change = -0.94) and dual smokers (Fold change = -1.04) when compared to NS (Fig 5A).

On plotting the results from comparing CS with rest of the study groups, we found few overlapping lncRNAs as shown in Fig 5B. Interestingly, the gene ID, TC0100010783.hg.1, was found to be commonly dysregulated in CS group when comparing with both E-cig and CSWP users. This gene encodes for the lnc-TDRD5, which has been shown to be responsible for chromatoid body assembly, retrotransposon silencing and spermiogenesis in mouse model [29].
| PROBEID    | GENENAME                          | log2 Fold change | P. Value       | Description                                      |
|------------|-----------------------------------|------------------|----------------|--------------------------------------------------|
| CS vs NS   |                                   |                  |                |                                                  |
| TC0300006839.hg.1 | uc062homo.1 // AC020626.1 // — // — | -0.576946781 | 4.22E-05      | Archived gene ID                                 |
| TC0400009975.hg.1 | poyvobo                          | 0.938840871      | 2.22E-05      | Homo sapiens single exon coding gene poyvobo     |
| TC0500011987.hg.1 | AC004777.1                       | -0.544358364     | 3.95E-05      | TEC tyrosine kinase                              |
| TC0700010745.hg.1 | AC007327.1                       | -0.568070439     | 2.95E-05      | Pseudogene similar to NADH dehydrogenase 2 MT-ND2 |
| TC0900011940.hg.1 | T368770 (miTranscriptome)         | -0.719952578      | 4.04E-05      | Unannotated                                      |
| TC1000012106.hg.1 | NA                               | 0.890647162      | 7.69E-05      | Unannotated                                      |
| TC1900010884.hg.1 | NA                               | -0.606841777     | 3.49E-05      | Unannotated                                      |
| E-cig vs NS |                                   |                  |                |                                                  |
| TC0400010170.hg.1 | skusworbu                        | -0.854161017     | 3.15E-05      | Putative Protein                                 |
| TC0500007633.hg.1 | lozorb y                         | 1.644179344      | 2.96E-05      | RNA-binding protein like family member.          |
| TC0600013228.hg.1 | SLC2A12                          | -0.792272819     | 3.95E-05      | Solute carrier family member 2 member            |
| TC0600014328.hg.1 | OSTM1                            | 0.764009224      | 1.32E-05      | Ostroclastogenesis associated transmembrane protein 1 |
| TC0700009611.hg.1 | Transfer RNA-Cys (GCA) 1–1       | 1.115171958      | 4.41E-05      | tRNA; Genhancer regulatory region                |
| TC0700010504.hg.1 | OSBPL3                           | 0.721080223      | 6.85E-05      | Oxysterol binding protein like 3                 |
| TC0700011130.hg.1 | T324413 (miTranscriptome)         | -0.862064073     | 2.30E-05      | Unannotated                                      |
| TC0800007080.hg.1 | BNIP3L                           | 3.736034539      | 2.80E-05      | Bcl2 interacting protein 3 like                  |
| TC0800007593.hg.1 | zoyerby                          | 1.81372327       | 4.40E-05      | Endonuclease reverse transcriptase family member |
| TC1300009105.hg.1 | Inc-PCDH20-13                    | 1.325335976      | 3.19E-05      | RNA gene                                         |
| TC1400006773.hg.1 | miR430                            | -0.779299012     | 3.36E-05      | micro RNA                                        |
| TC1700012104.hg.1 | T136883 (miTranscriptome)         | -1.361512953     | 4.10E-05      | Unannotated                                      |
| TC1900007497.hg.1 | flarchoy                         | 1.258862445     | 7.32E-05      | Endonuclease reverse transcriptase                |
| WP vs NS   |                                   |                  |                |                                                  |
| HTA2-pos-2909167_st | NA                             | 2.404401909     | 8.64E-05      | Normgene                                         |
| HTA2-pos-3281489_st | NA                             | 1.012476113     | 8.85E-05      | normgene                                         |
| TC0200013000.hg.1 | T191448 (miTranscriptome)         | 0.760037466      | 8.17E-05      | Unannotated                                      |
| TC0400009103.hg.1 | stoverswarby                     | 0.733276161      | 7.61E-05      | Spliced non-coding gene                          |
| TC0500006578.hg.1 | forgoy                           | -0.9250053       | 3.65E-05      | Putative Protein                                 |
| TC0500007285.hg.1 | Inc-ZNF131-1                     | 0.921228322      | 8.73E-05      | Antisense To ANXA2R                              |
| TC0600012815.hg.1 | PPIL6-201                        | 0.639890503      | 2.29E-06      | Peptidylprolyl isomerase like 6                  |
| TC0900009387.hg.1 | T354858 (miTranscriptome)         | -1.006431605     | 1.31E-05      | Unannotated                                      |
| TC0900011940.hg.1 | T368770 (miTranscriptome)         | -0.710249664     | 5.84E-05      | Unannotated                                      |
| TC0X00009996.hg.1 | AL590762.11                      | 0.659766654      | 6.96E-05      | Pseudogene Similar To Part Of Poly(A) Binding Protein, Nuclear 1 (PABPN1) |
| TC1000006801.hg.1 | T037261 (miTranscriptome)         | -0.777471484     | 7.50E-05      | Unannotated                                      |
| TC1100007618.hg.1 | LOC100129915                    | 0.780128991      | 6.59E-05      | Similar to ring finger protein 18                 |
| TC1100009966.hg.1 | AC068733.2–201                  | -0.576623305     | 3.90E-05      | TBC1 domain family, member 12, pseudogene       |
| TC1100010467.hg.1 | WT1                              | -0.941823433     | 8.02E-05      | WT1 transcription factor                         |
| TC1200006658.hg.1 | woybleby                         | -0.65889026      | 9.38E-05      | Putative mitochondrial protein                    |
| TC1300009108.hg.1 | T955410 (miTranscriptome)         | -0.55850742      | 9.48E-05      | Unannotated                                      |
| TC1500009732.hg.1 | fawkloy                          | 0.920293174      | 1.79E-05      | Putative Protein                                 |
| TC1600008382.hg.1 | T136042 (miTranscriptome)         | -1.137693624     | 9.45E-05      | Unannotated                                      |
| CSWP vs NS |                                   |                  |                |                                                  |
| TC0200010939.hg.1 | steerku                          | -0.900124606     | 1.27E-05      | Putative protein                                 |
| TC0200010952.hg.1 | NYAP2                            | 0.63991652       | 7.66E-05      | Neuronal tyrosine-phosphorylated phosphoinositide-3-kinase adaptor 2 |
| TC0300007087.hg.1 | blerfarbo                        | -0.948070038     | 7.95E-05      | Putative protein                                 |
### Table 1. (Continued)

| PROBEID       | GENENAME         | log2 Fold change | P. Value       | Description                                           |
|---------------|------------------|------------------|----------------|-------------------------------------------------------|
| **CS vs NS**  |                  |                  |                |                                                       |
| TC1100010467.hg.1 | WT1              | -1.042036815     | 4.89E-05       | WT1 transcription factor                              |
| TC1400010254.hg.1 | flopaw           | -0.65229696      | 7.53E-05       | Putative protein                                      |
| TC1600008900.hg.1 | sleebody         | 0.979624294      | 9.72E-05       | Putative protein                                      |
| TC1700010414.hg.1 | starsmo          | 2.01655418       | 4.44E-06       | Putative protein                                      |
| TC1800006738.hg.1 | smeypla          | 0.802532832      | 7.64E-05       | Putative protein of ancient origin                    |
| TC1900011559.hg.1 | T181991 (miTranscriptome) | 1.008317384 | 3.74E-06       | Unannotated                                           |
| **CS vs E-cig** |                  |                  |                |                                                       |
| AFX-r2-P1-cre-5_at | NA               | 0.55900778       | 4.04E-05       | Unannotated                                           |
| TC0100010783.hg.1 | Inc-TDRD5        | 0.68832216       | 2.81E-05       | RNA gene                                              |
| TC0100011659.hg.1 | Inc-MARK1-1      | -0.83026065      | 8.58E-06       | Non-protein coding Inc-MARK1-1:1 sequence.            |
| TC0100017504.hg.1 | T031766 (miTranscriptome) | -0.846997861  | 7.80E-05       | Unannotated                                           |
| TC0200007899.hg.1 | T191106 (miTranscriptome) | 0.785909826   | 5.65E-06       | Unannotated                                           |
| TC0500007170.hg.1 | T281110 (miTranscriptome) | 0.745643686    | 6.86E-05       | Unannotated                                           |
| TC0500007633.hg.1 | lozorby          | -1.56909552      | 4.82E-05       | RNA binding protein like family member                |
| TC0500009060.hg.1 | Inc-PCYOX1L-3    | 0.63048829       | 3.69E-05       | RNA gene                                              |
| TC0700006657.hg.1 | Asparagine-linked glycosylation 1-like 5 | 0.806480376 | 3.48E-05       | Genhancer regulatory region; pseudogene              |
| TC0700009611.hg.1 | Transfer RNA-Cys (GCA) 1–1 | -1.332318255  | 2.61E-06       | tRNA; Genhancer regulatory region                     |
| TC0800007593.hg.1 | zoyberby         | -1.79175151      | 4.46E-05       | Endonuclease reverse transcriptase family member      |
| TC0800012197.hg.1 | skorslubu        | 0.910130832      | 3.89E-05       | Tigger transposable element-derived protein 1 like family member |
| TC1000008542.hg.1 | T046708 (miTranscriptome) | -1.137097908    | 3.62E-05       | Unannotated                                           |
| TC1000012106.hg.1 | T050226 (miTranscriptome) | 0.98387836      | 8.45E-05       | Unannotated                                           |
| TC1200006995.hg.1 | pleyblubu        | -2.50688233      | 9.21E-05       | Spliced non-coding gene                               |
| TC1200007619.hg.1 | shanaw           | 0.853525764      | 6.10E-05       | Putative protein                                      |
| TC1300009313.hg.1 | seychoy         | -1.443895461     | 4.70E-05       | Single exon coding gene                               |
| TC1500009472.hg.1 | NA               | -0.88001693      | 7.51E-05       | Unannotated                                           |
| TC1500010310.hg.1 | RNA, U7 small nuclear 79 pseudogene | 0.504790762 | 5.35E-05       | Genhancer regulatory region                           |
| TC1600009730.hg.1 | T128938 (miTranscriptome) | 1.326826001    | 3.77E-05       | Unannotated                                           |
| TC1600010923.hg.1 | AC079414.1       | -1.30952335      | 2.38E-05       | Novel transcript, antisense to CLEC3A                 |
| TC1800009305.hg.1 | NONHSAG024018 92; Lnc-PIGN-6 | 0.748542125    | 9.87E-05       | Sense intronic non-coding RNA                         |
| **WP vs E-cig** |                  |                  |                |                                                       |
| TC0200014262.hg.1 | T199176 (miTranscriptome) | 0.69106882     | 5.31E-05       | Unannotated                                           |
| TC0500009060.hg.1 | Inc-PCYOX1L-3    | 0.590631549      | 4.53E-05       | RNA gene                                              |
| TC0800010424.hg.1 | T343804 (miTranscriptome) | -1.184148902  | 6.68E-05       | Unannotated                                           |
| TC0X00009996.hg.1 | AL590762.1       | 0.679813184      | 8.22E-05       | Pseudogene similar to part of poly(A) binding protein, nuclear 1 (PABPN1) |
| TC2100007196.hg.1 | T226511 (miTranscriptome) | 0.673584366    | 9.84E-05       | Unannotated                                           |
| **CSWP vs E-cig** |                  |                  |                |                                                       |
| TC0100009673.hg.1 | T018635 (miTranscriptome) | -1.604525926  | 9.79E-05       | Unannotated                                           |
| TC0200009307.hg.1 | PRSS40A         | -0.972747948     | 2.43E-05       | Serine protease 40A; pseudogene                       |
| TC0400007363.hg.1 | sheyfarby       | -1.270572291     | 2.14E-05       | Putative protein                                      |
| TC0600009394.hg.1 | bawplerbu       | 0.816447817      | 7.32E-06       | Putative protein                                      |
| TC0600013871.hg.1 | T315187 (miTranscriptome) | -0.871913931  | 9.62E-05       | Unannotated                                           |
| TC1700010414.hg.1 | starsmo         | 1.864419934      | 2.02E-05       | Putative protein                                      |
| TC2000008189.hg.1 | T212697 (miTranscriptome) | 0.726204194    | 3.26E-05       | Unannotated                                           |

(Continued)
| PROBEID       | GENENAME                      | log2 Fold change | P. Value       | Description                                                                 |
|--------------|-------------------------------|-----------------|----------------|-----------------------------------------------------------------------------|
| CS vs NS     |                               |                 |                |                                                                             |
| CS vs WP     |                               |                 |                |                                                                             |
| HTA2-pos-2909167_st | NA                      | -2.559642238    | 3.56E-05       | normgene                                                                     |
| TC0200007899.hg.1 | T191106 (miTranscriptome) | 0.730657071     | 3.84E-06       | Unannotated                                                                |
| TC0500007950.hg.1 | Inc-ATP6AP1L-5               | -1.050567649    | 5.72E-05       | RNA Gene; Genehancer regulatory elements.                                  |
| TC0600011203.hg.1 | ALO21918.1              | 0.958754545     | 1.92E-05       | WD repeat domain 59 (WDR59) pseudogene                                     |
| TC0Y00007289.hg.1 | rarsybo                  | -3.14407858     | 3.00E-05       | Single exon coding gene.                                                   |
| TC0Y00007291.hg.1 | warbo                    | -2.66655528     | 7.88E-05       | Single exon coding gene.                                                   |
| TC1500009732.hg.1 | fawkloy                | -0.934211892    | 1.35E-05       | Transcript Identified by AceView                                           |
| TC1900011062.hg.1 | T178086 (miTranscriptome) | 0.892397234     | 8.58E-05       | Unannotated                                                                |
| TSUnmapped00000088.hg.1 | DUSP16                | -0.879332008    | 5.01E-05       | Dual specificity phosphatase 16                                            |
| CSWP vs CS   |                               |                 |                |                                                                             |
| TC0100006493.hg.1 | smorarbo               | -0.986103904    | 7.76E-05       | Single exon coding gene                                                    |
| TC0100010783.hg.1 | Inc-TDRD5               | -0.619045364    | 7.43E-05       | RNA gene                                                                    |
| TC0100013974.hg.1 | RNF220                  | -0.799985122    | 8.80E-05       | Ring finger protein 220                                                    |
| TC0100015612.hg.1 | NONHSAT068475          | 0.554656506     | 3.89E-05       | Taqman probe, non-coding                                                   |
| TC0100017144.hg.1 | T029497 (miTranscriptome) | -0.895077856    | 7.51E-05       | Unannotated                                                                |
| TC0200007899.hg.1 | T191106 (miTranscriptome) | -0.710135209    | 1.57E-05       | Unannotated                                                                |
| TC0300007428.hg.1 | T242983 (miTranscriptome) | -0.783521911    | 6.85E-05       | Unannotated                                                                |
| TC0500009579.hg.1 | T294035 (miTranscriptome) | -0.820042957    | 7.02E-05       | Unannotated                                                                |
| TC0700006639.hg.1 | ACO04895.1–203         | -1.083546595    | 3.71E-05       | Novel transcript                                                           |
| TC1000012106.hg.1 | T050226 (miTranscriptome) | -1.063392127    | 1.84E-05       | Unannotated                                                                |
| TC1700010414.hg.1 | starsmo                | 2.004901352     | 4.52E-06       | Putative protein                                                           |
| CSWP vs WP   |                               |                 |                |                                                                             |
| HTA2-pos-3281489_st | NA                      | -1.090364457    | 6.09257E-05   | Normgene                                                                    |
| TC0300007367.hg.1 | KLHDC8B               | 0.883254947     | 4.89501E-05   | Kelch domain containing 8B                                                 |
| TC0600009394.hg.1 | bawplerbu           | 0.728763959     | 2.18613E-05   | Putative Protein                                                           |
| TC0600011929.hg.1 | Inc-CLICS-2         | 0.522529849     | 5.27087E-05   | Genehancer region                                                          |
| TC0700008587.hg.1 | T330053 (miTranscriptome) | -0.994276685    | 3.44684E-05   | Unannotated                                                                |
| TC0900008260.hg.1 | T363928 (miTranscriptome) | 0.919987054    | 3.95504E-05   | Unannotated                                                                |
| TC1000007657.hg.1 | T042202 (miTranscriptome) | 0.803560023    | 7.08706E-05   | Unannotated                                                                |
| TC1100006834.hg.1 | vaslorby             | 0.899127136     | 5.97471E-05   | Putative Protein                                                           |
| TC1200008270.hg.1 | Inc-NAV3-2:4          | 0.771483311     | 2.77469E-05   | Promoters and Genehancers                                                  |
| TC1300009889.hg.1 | T099623 (miTranscriptome) | -0.810946716    | 3.70585E-05   | Unannotated                                                                |
| TC1700010414.hg.1 | starsmo              | 2.001800176     | 3.72921E-06   | Putative Protein                                                           |
| TC1700011155.hg.1 | NA                   | 2.923514656     | 8.83794E-05   | Unannotated                                                                |

https://doi.org/10.1371/journal.pone.0243065.t001
Similarly, when we compared the differentially regulated genes amongst E-cig users to other groups (NS, CS, WP and CSWP) we found three lncRNAs that were commonly dysregulated. These genes IDs were TC0500007633.hg.1, TC0700009611.hg.1, TC0800007593.hg.1 which encoded for RNA binding protein (lozorby), tRNA-Cys (GCA)1-1, and endonuclease reverse transcriptase (zoyberby) respectively (Fig 5C).

Comparisons made between WP users with other groups has revealed some common targets across various comparisons. For example, two of the genes like HTA2-pos-2909167_st and TC1500009732.hg.1 (identified as fawkloy) were common and up regulated in WP on comparison with NS and CS (Fig 5D).

While comparing the lncRNA expression profiles for dual smokers (CSWP) versus all the other exposure groups, we found a common gene (TC1700010414.hg.1) that was upregulated amongst dual smokers. This gene codes for a putative protein, starsmo, and has exhibited approximately 2-fold increase in CSWP group when compared to NS, CS, WP or E-cig users (Fig 5E).

**Functional analysis of differentially expressed lncRNAs in plasma exosomes from non-smokers, smokers, E-cig users, waterpipe users and dual smokers**

Lastly, we performed FunRich gene enrichment analysis to perform functional annotation of the differentially expressed lncRNAs in various experimental groups. We found significant changes in the expression of lncRNAs involved in biological processes like, steroid metabolism, hemopoeisis and regulation of cell proliferation. The biological processes involving...
steroid metabolism are dysregulated amongst E-cig users as compared to non-smokers. When we enriched the differentially expressed genes based on their molecular functions, we again found a significant enrichment of genes involved in steroid binding which is enriched among the samples from E-cig users as compared to NS (Fig 6A & 6B).

Biological processes involved in cell differentiation and proliferation are significantly dysregulated amongst both waterpipe users and dual smokers as compared to non-smokers (Fig 6A). Most of the significant differentially expressed lncRNAs amongst E-cig users were intrinsic to membrane thus raising the possibility that E-cig use affects the cell membrane and related processes to the most (Fig 6C).

We did not find any significant change in the lncRNA expression when enriching the genes based on their involvement in various biological pathways or their site of expression (S1 Fig).

Discussion

Exposure to cigarette smoke is associated with various chronic diseases such as atherosclerosis, COPD, and lung cancer [30–34]. Similarly, exposure to waterpipe smoke has also been strongly linked with complications like heart disease, chronic bronchitis, and cancers [35, 36]. Recently, there has been a rapid rise in the number of E-cig users especially among the youth. Despite being marketed or sold as a safer alternative to traditional tobacco smoking, recent reports have associated the severe acute pulmonary illnesses with symptoms of eosinophilic, hypersensitivity pneumonitis and acute lung injury with vaping [37–41]. Further, there are reports of oxidative stress, endothelial cell dysfunction [42, 43], and altered innate immune response in lungs of E-cig users [44]. In fact, we have recently reported the altered expression of systemic biomarkers of inflammation and endothelial dysfunction in E-cig users [26].

Based on our recent studies on profiling of miRNA in smokers, E-cig users, Waterpipe smokers and dual users [23], we compared the exosomal lncRNA profiles in the blood plasma from NS, CS, WP, CSWP and E-cig users. Genome-wide association studies have identified
distinct loci associated with pulmonary pathologies like COPD, asthma, and IPF [1, 11–14]. These noncoding RNA (ncRNA) loci, encoding miRNAs, and IncRNAs, have been shown to play important roles in various cellular functions and diseases [1, 45–50]. Previous work by our lab has shown altered expression of exosomal miRNAs amongst our smoking and vaping groups [23]. Identifying the distinct IncRNA profiles amongst these groups was the main objective of this study that is critical in understanding the cellular mechanism altered following the use of various smoking/vaping products. The outcome of this study will further help in recognizing the pathologic biomarkers indicative of potential susceptibilities by vaping/smoking amongst these individuals.

We chose to use plasma-derived exosomes for this study as they are the most widely studied and extensively characterized exosomes [6, 51]. Blood plasma is easy to collect as compared to other biofluids like BALF and the method of isolation of exosomes (with high purity and yield) from blood plasma is well characterized [6, 52]. Furthermore, plasma and serum-derived exosomes have the potential to develop as biomarkers for various disease conditions [51, 53, 54]. We found alterations in a distinct set of IncRNA on exposure to E-cig vapor, cigarette smoke, waterpipe smoke and dual smoke, with slight overlaps. We showed altered expression of 13 IncRNA gene loci among E-cig users as compared to NS. Importantly, we observed a four-fold increase in the TC0800007080.hg.1 gene locus that encodes Bcl2 interacting protein 3 like-protein (BNIP3L). BNIP3L, also known as Nix, is a mitochondrial protein that is shown to promote airway epithelial cell injury on exposure to cigarette smoke [55]. In fact, increased expression of BNIP3L points towards aggravated mitophagy, which is a hallmark of pulmonary disease conditions including COPD and IPF [56, 57]. Furthermore, in vivo studies reveal that BNIP3L is the pro-apoptotic transcriptional target of p53. p53, also known as the guardian of the genome, is a tumor suppressive gene most commonly mutated in case of human cancers [58]. Thus, our results showing an attenuation in the BNIP3L expression on E-cig use raises the possibility of emergence of COPD, IPF or even cancers in these individuals. Gene enrichment analyses revealed a significant change (p = 0.049) in the expression of IncRNAs involved in steroid binding in the plasma-derived exosomes from E-cig users as compared to their non-smoking controls. This supports the findings from previous studies that show disruption in lipid metabolism on E-cig use [59–61].

On comparing the IncRNA profiles between WP users and NS, we found 18 altered gene loci. Amongst the known targets were PPIL6 and WT1. PPIL6 encodes peptidylprolyl isomerase like-6 protein that has been shown to be associated with respiratory immune responses in animals like lambs and swine [62, 63]. In fact, FK506-binding protein (FKBP)-a member of this class of proteins- has altered expression in asthma. Furthermore, it is also involved in the dysregulation of pro/anti-inflammatory genes and signaling proteins in COPD. However, its exact role remains largely unknown [64].

Similarly, the expression of Wilms tumor 1 (WT1), a marker of mesothelial cells, is known to be associated with fibrotic lungs in various cell types [65]. Evidence suggests that even partial loss of WT1 results in abrogation of pleural mesothelial cell phenotype and results in myofibroblast accumulation with upregulation in the expression of profibrotic markers- α-smooth muscle actin (α-SMA) and fibronectin [66, 67]. Our result showing decreased expression of WT1 in both waterpipe and dual smoker groups points towards the possible emergence of pulmonary fibrosis amongst these users. Overall, our study shows altered expression of IncRNAs in various exposure groups and identifies targets that point towards a possible risk of lung injury and/or related pathology amongst these individuals. Future studies designed to unravel the role of each of the identified IncRNAs will be crucial in identification and development of biomarkers for obstructive and/or restrictive lung pathologies.
Nevertheless, it is pertinent to mention, that our study had some limitations. First, though the GeneChip WT Pico assay is designed to be highly accurate, it may suffer from the technical issues inherent to microarrays including cross-and/or non-specific hybridization and limited detection range of individual probes [68]. As a result, some of the targets may not have been identified in this study. Second, a majority of the significantly altered IncRNAs identified in our study were not annotated with their associated functions unknown. Many others were defined as encoding putative proteins/peptides and their role in cellular signaling and gene regulation remain largely elusive. Yet, the growing interest in the area has unraveled important biomarkers and regulatory ncRNAs which are associated with tobacco smoke-related pathologies [69]. Third, analysis of exosomal IncRNAs has a major limitation of not being able to ascertain the cellular origins of the IncRNAs, which can be helpful in pathophysiology of a particular disease condition. Analysis of cellular IncRNAs from various blood or lung cells may help in providing a more specific biomarker signature for smoke-exposure associated diseases in the future.

Nonetheless, the present study is the first ever attempt to compare the exosomal IncRNA profiles of individuals using tobacco cigarettes, E-cig, waterpipe or both (cigarette and waterpipe). We identified some important targets that might play an important role in regulating the inflammatory or autophagic responses on long-term use of these products. Future work in this area is required to understand the functions of these IncRNAs and deducing their roles in relation to chronic lung pathologies caused by vaping and/or smoking.

Supporting information
S1 Fig. FunRich gene enrichment analysis of the differentially expressed IncRNAs. The top 6 enriched: (A) Biological pathway and (B) Site of expression for the significant IncRNAs and possible gene targets on pairwise comparisons between (i) E-cigarette users vs. Non-smokers, (ii) Waterpipe smokers vs. Non-smokers, and (iii) Dual smoker vs Non-smokers. NS, non-smoker; CS, cigarette smoker; E-cig, Electronic cigarette users; WP, waterpipe smoker; CSWP: Dual Smoker.

(PDF)

Acknowledgments
We thank Ms Janice Gerloff and Dr. Naushad Ahmad Khan (isolated exosomes and sent exosomal RNA for the analysis to Thermo Fisher) for initial recruitment of subjects and technical assistance. We also thank Dr. Isaac Sundar for helpful discussion and for providing scientific inputs.

Author Contributions
Conceptualization: Irfan Rahman.
Data curation: Gagandeep Kaur.
Formal analysis: Dongmei Li.
Funding acquisition: Irfan Rahman.
Investigation: Gagandeep Kaur, Kameshwar Singh, Krishna P. Maremanda.
Methodology: Gagandeep Kaur, Dongmei Li, Hitendra S. Chand.
Project administration: Irfan Rahman.
Resources: Kameshwar Singh, Krishna P. Maremmana, Hitendra S. Chand.  
Software: Dongmei Li.  
Supervision: Irfan Rahman.  
Writing – original draft: Gagandeep Kaur.  
Writing – review & editing: Kameshwar Singh, Krishna P. Maremmana, Dongmei Li, Hitendra S. Chand, Irfan Rahman.

References
1. Devadoss D., et al., Long Noncoding Transcriptome in Chronic Obstructive Pulmonary Disease. Am J Respir Cell Mol Biol, 2019. 61(6): p. 678–688. https://doi.org/10.1165/rcmb.2019-0184TR PMID: 31486667
2. Ma J., et al., Genome-wide analyses of long non-coding RNA expression profiles and functional network analysis in esophageal squamous cell carcinoma. Sci Rep, 2019. 9(1): p. 9162. https://doi.org/10.1038/s41598-019-45493-5 PMID: 31235759
3. Wang K.C. and Chang H.Y., Molecular mechanisms of long noncoding RNAs. Mol Cell, 2011. 43(6): p. 904–14. https://doi.org/10.1016/j.molcel.2011.08.018 PMID: 21925379
4. Hung T., et al., Extensive and coordinated transcription of noncoding RNAs within cell-cycle promoters. Nat Genet, 2011. 43(7): p. 621–9. https://doi.org/10.1038/ng.848 PMID: 21642992
5. Volders P.J., et al., LNCipedia 5: towards a reference set of human long non-coding RNAs. Nucleic Acids Res, 2019. 47(D1): p. D135–D139. https://doi.org/10.1093/nar/gky1031 PMID: 30371849
6. Huang X., et al., Characterization of human plasma-derived exosomal RNAs by deep sequencing. BMC Genomics, 2013. 14: p. 319. https://doi.org/10.1186/1471-2164-14-319 PMID: 23663390
7. Dragomir M., Chen B., and Calin G.A., Exosomal IncRNAs as new players in cell-to-cell communication. Transl Cancer Res, 2018. 7(Suppl 2): p. S243–S252. https://doi.org/10.21037/tcr.2017.10.46 PMID: 30148073
8. Coumans F.A.W., et al., Methodological Guidelines to Study Extracellular Vesicles. Circ Res, 2017. 120(10): p. 1632–1648. https://doi.org/10.1161/CIRCRESAHA.117.309417 PMID: 28495994
9. van Niel G., D'Angelo G., and Raposo G., Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol, 2018. 19(4): p. 213–228. https://doi.org/10.1038/nrm.2017.125 PMID: 29339798
10. Kelemen E., et al., Exosomal long non-coding RNAs as biomarkers in human diseases. EJIFCC, 2019. 30(2): p. 224–236. PMID: 31263395
11. Kubo H., Extracellular Vesicles in Lung Disease. Chest, 2018. 153(1): p. 210–216. https://doi.org/10.1016/j.chest.2017.06.026 PMID: 28684288
12. Li Y., et al., The roles of exosomal miRNAs and IncRNAs in lung diseases. Signal Transduct Target Ther., 2019. 4(1): p. 47. https://doi.org/10.1038/s41392-019-0080-7 PMID: 33177489
13. Alipoor S.D., et al., Exosomes and Exosomal miRNA in Respiratory Diseases. Mediators Inflamm., 2016. 2016: p. 5628404. https://doi.org/10.1155/2016/5628404 PMID: 27738390
14. Cazzoli R., et al., microRNAs derived from circulating exosomes as noninvasive biomarkers for screening and diagnosing lung cancer. J Thorac Oncol, 2013. 8(9): p. 1156–62. https://doi.org/10.1097/JTO.0b013e318299ac32 PMID: 23945385
15. Poullet C., et al., Exosomal Long Non-Coding RNAs in Lung Diseases. Int J Mol Sci, 2020. 21(10). https://doi.org/10.3390/ijms21103580 PMID: 32438606
16. Levänen B., et al., Altered microRNA profiles in bronchoalveolar lavage fluid exosomes in asthmatic patients. J Allergy Clin Immunol., 2013. 131(3): p. 894–903. https://doi.org/10.1016/j.jaci.2012.11.039 PMID: 2333113
17. Njock M.S., et al., Sputum exosomes: promising biomarkers for idiopathic pulmonary fibrosis. Thorax, 2019. 74(3): p. 309–312. https://doi.org/10.1136/thoraxjnl-2018-211897 PMID: 30244194
18. Bi H., et al., Microarray analysis of long non-coding RNAs in COPD lung tissue. Inflamm Res, 2015. 64(2): p. 119–26. https://doi.org/10.1007/s00011-014-0790-9 PMID: 25542208
19. Dai H. and Leventhal A.M., Prevalence of e-Cigarette Use Among Adults in the United States, 2014–2018. JAMA, 2019. 322(18): p. 1824–1827. https://doi.org/10.1001/jama.2019.15331 PMID: 31524940
20. General T.O.o.S., Surgeon General’s Advisory on E-cigarette Use Among Youth. 2019, US Department of Health and Human Services, Centers for Disease Control and Prevention (US): Atlanta, GA.
21. Salloum R.G., et al., Water pipe tobacco smoking in the United States: findings from the National Adult Tobacco Survey. Prev Med., 2015. 71: p. 88–93. https://doi.org/10.1016/j.ypmed.2014.12.012 PMID: 25535678

22. Soulakova J.N., et al., Prevalence and factors associated with use of hookah tobacco among young adults in the U.S. Addict Behav, 2018. 85: p. 21–25. https://doi.org/10.1016/j.addbeh.2018.05.007 PMID: 29803099

23. Singh K., et al., Exosomal microRNAs are novel circulating biomarkers in cigarette, waterpipe smokers, E-cigarette users and dual smokers. BMC Med Genomics, 2020, 13: 128. https://doi.org/10.1186/s12920-020-00748-3 PMID: 32912198

24. Jackson M., et al., Flavor Preference and Systemic Immunoglobulin Responses in E-Cigarette Users and Waterpipe and Tobacco Smokers: A Pilot Study. Int J Environ Res Public Health, 2020. 17(2). https://doi.org/10.3390/ijerph17020640 PMID: 31963835

25. Khan N.A., et al., Systemic biomarkers of inflammation, oxidative stress and tissue injury and repair among waterpipe, cigarette and dual tobacco smokers. Tob Control, 2019, 29(Suppl 2): p. s102–s109. https://doi.org/10.1136/tobaccocontrol-2019-054958 PMID: 31494573

26. Singh K.P., et al., Systemic biomarkers in electronic cigarette users: implications for noninvasive assessment of vaping-associated pulmonary injuries. ERJ Open Res, 2019. 5(4). https://doi.org/10.1183/23120541.00182-2019 PMID: 31886159

27. Sundar I.K., Li D., and Rahman I., Small RNA-sequence analysis of plasma-derived extracellular vesicle microRNAs in smokers and patients with chronic obstructive pulmonary disease as circulating biomarkers. J Extracell Vesicles, 2019. 8(1): p. 1684816. https://doi.org/10.1080/20013078.2019.1684816 PMID: 31762962

28. Rix K., Industry News: New GeneChip® WT Pico Kit Prepares Array Target from Picogram Amounts of RNA, in SelectScience. 2015.

29. Yabuta Y., et al., TDRD5 is required for retrotransposon silencing, chromatin body assembly, and spermiogenesis in mice. J Cell Biol, 2011. 192(5): p. 781–95. https://doi.org/10.1083/jcb.201009043 PMID: 21383078

30. Howard G., et al., Cigarette smoking and progression of atherosclerosis: The Atherosclerosis Risk in Communities (ARIC) Study. JAMA, 1998. 279(2): p. 119–24. https://doi.org/10.1001/jama.279.2.119 PMID: 9440661

31. Siasos G., et al., Smoking and atherosclerosis: mechanisms of disease and new therapeutic approaches. Curr Med Chem, 2014. 21(34): p. 3936–48. https://doi.org/10.2174/092986731411015161539 PMID: 25174928

32. Caramori G., et al., Molecular pathogenesis of cigarette smoking-induced stable COPD. Ann N Y Acad Sci, 2015. 1340: p. 55–64. https://doi.org/10.1111/nyas.12619 PMID: 25639503

33. Pesch B., et al., Cigarette smoking and lung cancer—relative risk estimates for the major histological types from a pooled analysis of case-control studies. Int J Cancer, 2012. 131(5): p. 1210–9. https://doi.org/10.1002/ijc.27339 PMID: 22052239

34. Houghton A.M., Mechanistic links between COPD and lung cancer. Nat Rev Cancer, 2013. 13(4): p. 233–45. https://doi.org/10.1038/nrc3477 PMID: 23467302

35. Qasim H., et al., The effects of hookah/water pipe smoking on general health and the cardiovascular system. Environ Health Prev Med, 2019. 24(1): p. 58. https://doi.org/10.1186/s12199-019-0811-y PMID: 31521105

36. Mamtani R., et al., Cancer risk in waterpipe smokers: a meta-analysis. Int J Public Health, 2017. 62(1): p. 73–83. https://doi.org/10.1007/s00038-016-0856-2 PMID: 27421466

37. Sommerfeld C.G., et al., Hypersensitivity Pneumonitis and Acute Respiratory Distress Syndrome From E-Cigarette Use. Pediatrics, 2018. 141(6). https://doi.org/10.1542/peds.2016-3927 PMID: 29773665

38. Arter Z.L., et al., Acute eosinophilic pneumonia following e-cigarette use. Respir Med Case Rep, 2019. 27: p. 100825. https://doi.org/10.1016/j.rmcr.2019.100825 PMID: 30963023

39. Anderson R.P. and Zechar K., Lung injury from inhaling butane hash oil mimics pneumonia. Respir Med Case Rep, 2019. 26: p. 171–173. https://doi.org/10.1016/j.rmcr.2019.01.002 PMID: 30671339

40. He T., et al., "Tree-in-Bloom": Severe Acute Lung Injury Induced by Vaping Cannabis Oil. Ann Am Thorac Soc, 2017. 14(3): p. 468–470. https://doi.org/10.1513/AnnalsATS.201612-974LE PMID: 28248584

41. Chand H.S., et al., Pulmonary toxicity and the pathophysiology of electronic cigarette, or vaping product, use associated lung injury. Front Pharmacol., 2019. 10: 1619. https://doi.org/10.3389/fphar.2019.01619 PMID: 31992985

42. Igashi Y., et al., Endothelial function and oxidative stress in cardiovascular diseases. Circ J, 2009. 73 (3): p. 411–8. https://doi.org/10.1253/circj.cj-08-1102 PMID: 19194043
43. Chatterjee S., et al., Acute exposure to e-cigarettes causes inflammation and pulmonary endothelial oxidative stress in nonsmoking, healthy young subjects. Am J Physiol Lung Cell Mol Physiol, 2019. 317 (2): p. L155–L166. https://doi.org/10.1152/ajplung.00110.2019 PMID: 31042077

44. Reidel B., et al., E-Cigarette Use Causes a Unique Innate Immune Response in the Lung, Involving Increased Neutrophilic Activation and Altered Mucin Secretion. Am J Respir Crit Care Med, 2018. 197 (4): p. 492–501. https://doi.org/10.1164/rccm.201708-1590OC PMID: 29053025

45. Devados D., et al., A long noncoding RNA antisense to ICAM-1 is involved in allergic asthma associated hyperreactive response of airway epithelial cells. Mucosal Immunol, 2020, https://doi.org/10.1038/s41385-020-00352-9 PMID: 33122732

46. Ponting C.P., Oliver P.L., and Reik W., Evolution and functions of long noncoding RNAs. Cell, 2009. 136(4): p. 629–41. https://doi.org/10.1016/j.cell.2009.02.006 PMID: 19239885

47. Guttman M. and Rinn J.L., Modular regulatory principles of large non-coding RNAs. Nature, 2012. 482 (7385): p. 339–46. https://doi.org/10.1038/nature10887 PMID: 22337053

48. Elling R., Chan J., and Fitzgerald K.A., Emerging role of long noncoding RNAs as regulators of innate immune cell development and inflammatory gene expression. Eur J Immunol, 2016. 46(3): p. 504–12. https://doi.org/10.1002/eji.201445558 PMID: 26820238

49. Fang J., Sun C.C., and Gong C., Long noncoding RNA XIST acts as an oncogene in non-small cell lung cancer by epigenetically repressing KLF2 expression. Biochem Biophys Res Commun, 2016. 478(2): p. 811–7. https://doi.org/10.1016/j.bbrc.2016.08.030 PMID: 27501756

50. Chinnapayyan S., et al., Role of Non-Coding RNAs in Lung Circadian Clock Related Diseases. Int J Mol Sci, 2020. 21(8):3013. https://doi.org/10.3390/ijms21083013 PMID: 32344623

51. Meng X., et al., Circulating exosomes and their cargos in blood as novel biomarkers for cancer. TCR, 2017: p. S226–S242.

52. Cumba Garcia L.M., et al., Isolation and Analysis of Plasma-Derived Exosomes in Patients With Glioma. Front Oncol., 2019. 9(651). https://doi.org/10.3389/fonc.2019.00651 PMID: 31380286

53. Shi R., et al., Exosomal levels of miRNA-21 from cerebrospinal fluids associated with poor prognosis and tumor recurrence of glioma patients. Oncotarget, 2015. 6(29): p. 26971–81. https://doi.org/10.18632/oncotarget.4699 PMID: 30618073

54. Skog J., et al., Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol, 2008. 10(12): p. 1470–6. https://doi.org/10.1038/ncb1800 PMID: 19011622

55. Zhang M., et al., Nix/BNIP3L-dependent mitophagy accounts for airway epithelial cell injury induced by cigarette smoke. J Cell Physiol, 2019. 234(8): p. 14210–14220. https://doi.org/10.1002/jcp.28117 PMID: 30618073

56. Leermakers P.A., et al., Molecular signalling towards mitochondrial breakdown is enhanced in skeletal muscle of patients with chronic obstructive pulmonary disease (COPD). Sci Rep, 2018. 8(1): p. 15007. https://doi.org/10.1038/s41598-018-33471-2 PMID: 30302028

57. Tsubouchi K., Araya J., and Kuwano K., PINK1-PARK2-mediated mitophagy in COPD and IPF pathogeneses. Inflamm Regener, 2018. 38: p. 18–18. https://doi.org/10.1186/s41232-018-0077-6 PMID: 30386443

58. Fei P., et al., Bnip3L is induced by p53 under hypoxia, and its knockdown promotes tumor growth. Cancer Cell, 2004. 6(6): p. 597–609. https://doi.org/10.1016/j.ccr.2004.10.012 PMID: 15607964

59. Madison M.C., et al., Electronic cigarettes disrupt lung lipid homeostasis and innate immunity independent of nicotine. J Clin Invest, 2019. 129(10): p. 4290–4304. https://doi.org/10.1172/JCI128631 PMID: 31483291

60. Cardenia V., et al., The effect of electronic-cigarettes aerosol on rat brain lipid profile. Biochimie, 2018. 153: p. 99–108. https://doi.org/10.1016/j.biochi.2018.07.027 PMID: 30077815

61. Maddock S.D., et al., Pulmonary Lipid-Laden Macrophages and Vaping. NEJM, 2019. 381(15): p. 1488–1489. https://doi.org/10.1056/NEJMct1912036 PMID: 31491073

62. McRae K.M., et al., Genome-wide association study of lung lesions and pleurisy in New Zealand lambs1. Journal of Animal Science, 2018. 96(11): p. 4512–4520. https://doi.org/10.1093/jas/sky323 PMID: 30099550

63. Zanella R., et al., Unravelling the genetic components involved in the immune response of pigs vaccinated against influenza virus. Virus Res, 2015. 210: p. 327–36. https://doi.org/10.1016/j.viruses.2015.09.003 PMID: 26362524

64. Holownia A., et al., Increased FKBP51 in induced sputum cells of chronic obstructive pulmonary disease patients after therapy. Eur J Med Res, 2009. 14 Suppl 4(Suppl 4): p. 108–111. https://doi.org/10.1186/2047-783x-14-a4-108 PMID: 20156738
65. Sontake V., et al., Fibrocytes Regulate Wilms Tumor 1-Positive Cell Accumulation in Severe Fibrotic Lung Disease. J Immunol, 2015. 195(8): p. 3978–91. https://doi.org/10.4049/jimmunol.1500963 PMID: 26371248

66. Sontake V., et al., Wilms’ tumor 1 drives fibroproliferation and myofibroblast transformation in severe fibrotic lung disease. JCI insight, 2018. 3(16): p. e121252. https://doi.org/10.1172/jci.insight.121252 PMID: 30135315

67. Karki S., et al., Wilms’ tumor 1 (WT1) regulates pleural mesothelial cell plasticity and transition into myofibroblasts in idiopathic pulmonary fibrosis. Faseb j, 2014. 28(3): p. 1122–31. https://doi.org/10.1096/fj.13-236828 PMID: 24265486

68. Zhao S., et al., Comparison of RNA-Seq and microarray in transcriptome profiling of activated T cells. PloS one, 2014. 9(1): p. e78644–e78644. https://doi.org/10.1371/journal.pone.0078644 PMID: 24454679

69. Soares do Amaral N., et al., Noncoding RNA Profiles in Tobacco- and Alcohol-Associated Diseases. Genes, 2016. 8(1): p. 6. https://doi.org/10.3390 Genes8010006 PMID: 28025544